Showing 5631-5640 of 8791 results for "".
- EWG Surveys Personal Care Product Companies About Removing 1,4-Dioxanehttps://practicaldermatology.com/news/ewg-surveys-personal-care-product-companies-about-removing-14-dioxane/2458220/The Environmental Working Group (EWG) is surveying U.S. makers of personal care products to ask if they are working to remove 1,4-dioxane, a potential human carcinogen, from their products. At least 8,000 products on the market contain ethoxylated ingredie
- Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trialhttps://practicaldermatology.com/news/nolan-positive-topline-results-with-fungicidal-sb208-in-phase-2-trial/2458222/Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan’s SB208 Gel, at bo
- Phase 4 Studies of Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefithttps://practicaldermatology.com/news/phase-4-studies-of-restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit/2458226/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategyhttps://practicaldermatology.com/news/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations-strategy/2458224/Daphne Karydas is Allergan’s new Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq
- Apax Partners To Acquire Syneron for Close to $400 millionhttps://practicaldermatology.com/news/apax-partners-to-acquire-syneron-for-close-to-400-million/2458230/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price repr
- FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Informationhttps://practicaldermatology.com/news/fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-humira-prescribing-information/2458232/The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Humira is the first biologic treatment with data on fingernail psoriasis in its US prescribing
- Dr. George J. Hruza Elected AAD President-Electhttps://practicaldermatology.com/news/dr-george-j-hruza-elected-aad-president-elect/2458231/George J. Hruza, MD, MBA, FAAD, has been elected president-elect of the American Academy of Dermatology (AAD). Dr. Hruza also will hold this position for the American Academy of Dermatology Association. He will be installed as president-elect in February 2018 and hold the office of president for
- Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trialshttps://practicaldermatology.com/news/allergan-and-paratek-pharmaceuticals-acne-drug-performs-well-in-phase-3-trials/2458234/Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived anti